Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
P/B ratio for Instil Bio, Inc. (TIL)
P/B ratio as of 2023: 0.22
According to Instil Bio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.22. At the end of 2022 the company had a P/B ratio of 0.22.
P/B ratio history for Instil Bio, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.22 |
| 2022 | 0.22 |
| 2021 | 3.98 |
| 2020 | -85.61 |
| 2019 | -491.86 |